• About Trist
  • What is TroVax
  • Trial objectives
  • Trial locations
• For Patients
  • Trial information
  • Renal cancer
• For Clinicians
  • Trial design
  • Trial objectives
  • Patient population
• Other Trials
  • QUASAR V
  • FLAMENCO
  • Phase II HPRC
• Contact Us

The Phase III trial, TRIST, is designed to demonstrate definitively that TroVax is effective as a treatment for renal cell carcinoma. It will compare the responses of patients who are treated with TroVax in combination with one of the standard therapies for the disease (interleukin-2, interferon-alpha or sunitinib) with those patients who are given a placebo in combination with standard treatment. TroVax's effectiveness will be measured as its ability to prolong the survival of patients. The rate and amount that the tumours respond to treatment, the length of time that patients survive without the progression of their disease, and patients’ quality of life will also be measured and compared between the trial and control groups.

Oxford BioMedica is the innovator of TroVax and is developing the product in collaboration with sanofi-aevntis.

Website by College Hill - Life Sciences